's () James Barder tells Proactive London's Andrew Scott they've seen little impact from the coronavirus lockdown and that regulatory submissions for its erectile dysfunction treatment remain on track.
The treatment is MED3000 - a fast-acting gel that will be targeted at men for whom the current treatments don’t work.
Barder says a second pre-submission meeting with the US Food & Drug Administration has been now set.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Futura Medical PLC named herein, including the promotion by the Company of Futura Medical PLC in any Content on the Site, the Company receives...
FOR OUR FULL DISCLAIMER CLICK HERE